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Abstract Friedreich ataxia is the consequence of frataxin
deficiency, most often caused by a GAA repeat expansion in
intron 1 of the corresponding gene. Frataxin is a mitochondrial
protein involved in iron homeostasis. As an attempt to generate a
mouse model of the disease, we introduced a (GAA)230 repeat
within the mouse frataxin gene by homologous recombination.
GAA repeat knockin mice were crossed with frataxin knockout
mice to obtain double heterozygous mice expressing 25^36% of
wild-type frataxin levels. These mice were viable and did not
develop anomalies of motor coordination, iron metabolism or
response to iron loading. Repeats were meiotically and
mitotically stable. ß 2002 Federation of European Biochemi-
cal Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Friedreich ataxia (FRDA) is the most common autosomal
recessive ataxia in caucasians, with an estimated prevalence of
2^4 per 100 000 individuals [1^3]. The neuropathology in
FRDA is characterized by loss of large sensory neurons in
the dorsal root ganglia, atrophy of the large sensory ¢bers
in peripheral nerves, of the posterior columns, spinocerebellar
and pyramidal tracts in the spinal cord and of the dentate
nucleus in the cerebellum [4]. Patients show progressive gait
and limb ataxia, dysarthria, lower limbs are£exia, decreased
vibration sense, muscle weakness in the legs, and positive ex-
tensor plantar responses [5^8]. Most patients also have hyper-
trophic cardiomyopathy, and about one third have diabetes or
carbohydrate intolerance [9^12].
FRDA is typically caused by a large GAA repeat expansion
(ranging from 100 to more than 1100 repeats) within the ¢rst
intron of the gene encoding a protein called frataxin [13]. 96%
of patients are homozygous for the GAA repeat expansion,
while the remaining are compound heterozygous for a GAA
expansion and a point mutation that alters or truncates the
coding region of the gene [13,14]. The GAA repeat expansion
has been shown to inhibit frataxin transcription [15,16]. Lym-
phoblastoid cell lines from FRDA patients have a severe re-
duction in the expression of frataxin, ranging from 4% to 29%
of normal levels [17].
Frataxin is a 210 amino acid nuclear-encoded mitochon-
drial protein that is highly conserved throughout evolution
[13,18]. The frataxin homolog in yeast is involved in iron
homeostasis, as indicated by the analysis of frataxin knockout
yeast (vYFH1). YFH1 accumulates 10-fold more iron in mi-
tochondria than wild-type yeast, loses mitochondrial DNA,
and is unable to carry out oxidative phosphorylation [19].
The mechanism of mitochondrial iron accumulation is un-
known, but the reintroduction of yeast frataxin results in a
rapid export of accumulated mitochondrial iron into the cy-
tosol as free, non-heme-bound iron [20]. Several lines of evi-
dence indicate that the function of frataxin is conserved in
humans. Work by Cavadini and colleagues has shown that
human frataxin cDNA can complement the frataxin-de¢cient
yeast, suggesting that frataxin function is conserved and re-
inforcing the idea that human frataxin is involved in mito-
chondrial iron homeostasis [21].
Studies in the mouse have shown that frataxin plays an
important role during early embryonic development, since ho-
mozygous frataxin knockout mice die in utero shortly after
implantation at embryonic day (E)6.5 [22]. In order to devel-
op an animal model for FRDA to investigate the function of
frataxin, the mechanism of the disease, and test possible treat-
ments, we generated a knockin mouse that carries a (GAA)230
repeat expansion in the ¢rst intron of the mouse frataxin
homolog gene (frda).
2. Materials and methods
2.1. Construction of the targeting vector
A cloned BamHI^BglII fragment from intron 1 of the frataxin gene,
containing a (GAA)230 repeat and a £anking sequence of 350 bp up-
stream and 250 bp downstream, was obtained as described in [16].
This fragment was inserted in the XbaI/BsiIw site of the MFneoTK
vector, which contains a phosphoglycerate kinase promoter/neomycin
resistance gene cassette, £anked by loxP sites in the same orientation
as the GAA repeat. This MFNeoTKGAA230 construct was then
cloned into the ¢rst intron of the frda gene, which was contained in
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a cosmid clone along with the ¢rst and second exon of the gene. The
complete construct was introduced into Escherichia coli DH5K by
electroporation.
2.2. Gene targeting in ES cells and generation of chimeras
Following linearization at the unique SalI site, the targeting vector
was electroporated into 129/Sv ES cells grown on feeder layers. After
G418 selection, the DNA of resistant clones was analyzed by PCR
using primers GAA-F and GAA-R [13]. To generate chimeras, tar-
geted ES cells were injected into C57BL/6J host blastocysts, which
were then transferred into pseudo-pregnant females. Male chimeras
were selected by coat color and crossed with C57BL/6J females to
obtain germline transmission of the targeted frda230GAA allele.
2.3. Animals
The Institutional Animal Care Committee reviewed and approved
all procedures performed in accordance with the Canadian Council on
Animal Care guidelines. Frataxin heterozygous knockin mice
(frda=230GAA) were crossed to generate frataxin homozygous knockin
mice (frda230=230GAA). To further decrease frataxin expression, frataxin
heterozygous knockout mice (frda=3) [22] were crossed with
frda=230GAA mice, to generate frataxin knockout/knockin mice
(frda3=230GAA).
2.4. Genotype analysis
Genomic DNA was prepared from tail biopsies. Mouse genotyping
included a set of two multiplex PCRs speci¢c for the knockout and
knockin frda loci. The multiplex PCR for genotyping the knockin
allele includes a common forward primer (P1: 5P-TTAGACAGA-
CATGCACAAACAGAAT-3P) and two reverse primers speci¢c for
the wild-type (P2: 5P-TGT GGG TGA CCT TGG AGG GAG-3P)
and knockin (P3: 5P-CCT AAC TTT TAA GCA CTG GCA AC-3P)
frda alleles. PCR products are 313 bp for the wild-type allele and 230
bp for the knockin allele (Fig. 1B). The multiplex PCR for genotyping
the frda knockout allele includes a common forward primer (WJ5: 5P-
CTGTTTACCATGGCTGAGATCTC-3P) and two reverse primers
speci¢c for the wild-type (WN39: 5P-CCA AGG ATA TAA CAG
ACA CCA TT-3P) and knockout (WC76: 5P-CGC CTC CCC TAC
CCG GTA GAA TTC-3P) frda alleles [22]. The PCR products are 520
bp for the wild-type allele and 245 bp for the knockout allele (Fig.
1C).
2.5. Quanti¢cation of frataxin expression by PCR LightCycler
Dissected mouse hearts were immediately extracted for RNA using
the Trizol reagent (Gibco BRL, Rockville, MD, USA). cDNA syn-
thesis was performed as described [34]. RNA (5 Wg) was converted to
cDNA using M-MuLV-RTase (Gibco BRL) at 37‡C for 1 h. The
cDNA samples were digested with RNase A for 2 min and followed
by Qiagen puri¢cation column. PCR was performed in a LightCycler
from Roche Molecular Biochemicals. The two primers used for am-
pli¢cation were: 5P-GCC CAT TTG AAC CTC CAC TAC C-3P and
5P-CTT GTT TGG GGT CTG CTT GTT G-3P. Sybergreen I (Mo-
lecular Probe, Eugene, OR, USA) was used as a £uorescence indica-
tor. A total of 40 cycles were run under the following conditions:
denaturing 95‡C, 1 s; annealing 57‡C, 1 s; elongation 72‡C, 10 s.
The melting cycle was performed as 95‡C (1 s), 40‡C (20 s), 95‡C
(1 s). The PCR quanti¢cation was normalized by internal control
L-actin. The frataxin expression level was reported as percentage to
wild-type mice.
2.6. Western blot analysis
Tissues were homogenized in 10 volumes of Laemmli bu¡er and
Fig. 1. A: Targeting strategy for the insertion of a (GAA)230 repeat expansion into intron 1 of the mouse frataxin gene. The genomic structure
of the wild-type locus encompassing exon 1^3 (black boxes) is depicted at the top. The targeting plasmid is represented in the middle. P1^P3,
primers used for genotyping mouse DNA by multiplex PCR. B: PCR analysis for detection of frataxin knockin allele. C: PCR analysis for de-
tection of frataxin knockout allele. Lane 1: ladder 100 bp; lane 2: frda230=230GAA ; lane 3: frda=3 ; lane 4: wild-type; lanes 5 and 6:
frda3=230GAA.
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adjusted to a ¢nal protein concentration of 15 Wg/Wl, using the Sigma
protein assay following the manufacturer’s protocol (Sigma, St. Louis,
MO, USA). 20 Wg of each homogenate were loaded onto a 12% Tris^
glycine sodium dodecyl sulfate (SDS)^polyacrylamide gel, run by elec-
trophoresis and then blotted onto a Hybond-C super (Amersham-Life
Science, Arlington Heights, IL, USA) membrane. Blots were probed
with a monoclonal antibody to frataxin (Chemicon, Temecula, CA,
USA) as well as a monoclonal antiserum to L-tubulin (Calbiochem,
San Diego, CA, USA) to compare protein concentration for each
sample. Speci¢c signals were visualized by chemiluminescence. Quan-
ti¢cation of frataxin expression was determined by analyzing auto-
radiograms with Scion imager software (Scion Corporation, MD,
USA). The intensity of each frataxin band was corrected according
to the intensity of the L-tubulin band for that same lane. Wild-type
and frataxin knockout heterozygous mice were used as controls for
the amount of frataxin.
2.7. Serum iron and transferrin saturation
Blood was collected by heart puncture under pentobarbital anes-
thesia, and serum was separated. Serum iron and total iron-binding
capacity were determined by a colorimetric assay using a Kodak Ek-
tachem DT60 instrument (JohnsonpJohnson, Clinical Diagnostics).
2.8. Diets
Dietary iron loading was obtained by placing 6-week-old mice on
an iron-enriched diet containing 3% (w/w) carbonyl^iron (Sigma, St.
Louis, MO, USA), for a period of 2 months. To induce parenteral
iron loading, 5 mg of iron^dextran (Sigma) were injected i.p., three
times per week, for a total amount of 85 mg/mouse, during a period
of 2 months.
2.9. Measurement of tissue iron levels
Organ samples were weighed wet, then dried overnight at 106‡C
and weighed again. The dried samples were ashed in an oven at 500‡C
for 17 h, solubilized in 6 N HCl, and the ¢nal solution was adjusted
with demineralized water to a ¢nal concentration of 1.2 mol/l. Iron
concentration was determined by £ame atomic absorption spectrom-
etry.
2.10. Size of GAA repeat
To determine the size of the GAA repeat, fragments were ampli¢ed
using the primers GAA-F2 (5P-GAT CAC CTG AGG TCC GGA
GTT CAA GAC T-3P) and GAAR-R2 (5P-GAT TCT CCT GCC
GCA GCC TCT GGA GTA GC-3P). The PCR products were run
overnight in a 0.8% agarose gel at 40 V. The expected fragment size is
890 bp.
2.11. Histology
Tissue samples from liver, spleen, heart and pancreas were ¢xed in
bu¡ered 4% formaldehyde and embedded in para⁄n. Tissue sections
were stained with hematoxilin/eosin and trichrome blue for demon-
stration of ¢brosis. Ferric iron (Fe(III)) was detected by Prussian blue
staining.
2.12. Rotarod analysis
Motor coordination and balance were assessed using an accelerat-
ing rotarod apparatus (Stoelting Co, Wood Dale, IL, USA). Mice
were trained in four trials (T1^T4) per day for 4 consecutive days
(D1^D4). Each trial lasted a maximum of 10 min, during which
time the rotating rod accelerates from 4 to 40 rpm over the ¢rst
5 min of the trial and was then held at maximum speed for the
remaining 5 min. A minimum of 10 min between trials was allowed
to avoid animal fatigue and exhaustion.
3. Results
3.1. Generation of frataxin knockin mice
The major cause of FRDA is the presence in homozygosity
of a large GAA repeat expansion in the ¢rst intron of the
frataxin gene, that decreases frataxin expression to less than
30% of normal levels [17]. With the aim to generate an animal
model showing a reduction in frataxin expression similar to
FRDA patients, we generated a frataxin knockin mouse by
targeting a GAA repeat expansion to intron 1 of the mouse
frataxin gene. A fragment containing a (GAA)230 repeat ex-
pansion, originally cloned from a FRDA patient, was inserted
in the mouse genome by homologous recombination (Fig.
1A). Male chimeras were selected by coat color and crossed
with C57BL/6J females to obtain germline transmission of the
targeted frda230GAA allele.
3.2. Frataxin levels in frataxin knockin/knockout mice
Levels of frataxin expression in skeletal muscle, heart,
brain, spleen, pancreas, and liver of both knockin and knock-
in/knockout mice were analyzed by Western blot (Fig. 2A).
Densitometric analysis of Western blots indicates that the
presence of a (GAA)230 repeat in homozygous frataxin knock-
in mice (frda230=230GAA) leads to a reduction in the levels of
frataxin expression in all tissues examined, averaging 75% of
wild-type levels. Nevertheless, these values of frataxin expres-
sion were still too high to expect the mice to develop a
FRDA-like phenotype, since frataxin knockout mice
(frda=3), which have approximately 50% of frataxin levels
Fig. 2. Frataxin levels are reduced in homozygous frataxin knockin
and in knockin/knockout mice, when compared to wild-type mice.
A: Total protein extract (20 Wg) from mouse tissues was immuno-
blotted with frataxin and L-tubulin antibodies. Lane 1, wild-type;
lane 2, frda=3 ; lane 3, frda230=230GAA ; lane 4, frda3=230GAA. Densi-
tometric analysis of frataxin protein expression is shown below.
B: Total RNAs were isolated from the hearts of wild-type and mu-
tant mice, and RT-PCR was carried out with frataxin-speci¢c prim-
ers. The PCR quanti¢cation was normalized by internal control
-actin. The frataxin expression levels are reported as percentage to
wild-type mice.
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when compared to wild-type mice are phenotypically indistin-
guishable from their control littermates [23]. In order to fur-
ther decrease frataxin levels, we crossed frataxin knockin mice
with frda=3 mice, thus generating knockin/knockout mice
(frda3=230GAA). Analysis of frataxin expression in tissues
from frda3=230GAA mice shows a reduction of frataxin to 25
to 36% of wild-type mice levels (Fig. 2). This value lies within
the range of expression reported in mildly a¡ected FRDA
patients [17].
3.3. Characterization of frataxin knockin/knockout mice
Clinical features in FRDA patients include uncoordinated
gait and limb movements (ataxia), diminished or absent ten-
don re£exes, and impairment of proprioreception and bal-
ance. We investigated frda3=230GAA mice for FRDA-like
symptoms by testing their motor coordination and balance
using an accelerating rotarod apparatus. Tests were per-
formed every 3 months starting at the age of 1 month (Fig.
3). Since symptoms in humans appear progressively, we fol-
lowed these mice over a period of 1 year. Frda3=230GAA mice
performed similarly as the wild-type mice on the rotarod, up
to the age of 1 year.
Frataxin a¡ects iron homeostasis in mitochondria [19,21],
therefore we analyzed iron metabolism in frda3=230GAA mice.
Levels of serum iron, transferrin saturation, and tissue iron
concentration were determined in 1-year-old mice. Serum iron
and transferrin were in the normal range (data not shown).
Total iron concentration in tissues were similar in
frda3=230GAA mice and their wild-type littermates (Table 1),
except in pancreas, where iron levels were lower in
frda3=230GAA mice (P6 0.01).
The heart is a¡ected in the vast majority of FRDA patients
[9,14,24] and shows intracellular iron deposits in cardiomyo-
cytes [25] related to heart ¢brosis. We analyzed heart samples
from 1-year-old frda3=230GAA mice for the presence of iron
and collagen deposition. No iron deposits and only mild col-
lagen staining, especially around vessels, were observed in
both frda3=230GAA and wild-type mice.
One out of twelve frda=3 mice, and two out of 13
frda3=230GAA mice died during the time course of the experi-
ment. No deaths were recorded in wild-type and
frda230=230GAA mice during the same period of time. Interest-
ingly, one frda3=230GAA mouse that died at the age of 12
months had levels of iron in the heart almost three times
higher than its littermates (1168 Wg, average 399 Wg Fe/g dry
weight), and prominent heart ¢brosis.
3.4. E¡ect of iron challenge in frataxin double heterozygous
mice
We next studied the response of frda3=230GAA mice to iron
Fig. 3. Motor coordination in frda230=230GAA and frda3=230GAA mice is indistinguishable from wild-type littermates, as evaluated by the accelerat-
ing rotarod. Data are presented as means þ S.E.M.
Table 1
Tissue iron concentration
Mice n Liver Heart Pancreas Spleen
Wg Fe/g dry weight
frda= 8 227 þ 59 412 þ 85 175 þ 24 3048 þ 1438
frda=3 12 292 þ 84 372 þ 28 183 þ 43 1741 þ 669*
frda230=230 GAA 9 247 þ 72 431 þ 56 159 þ 75 3206 þ 1339
frda3=230 GAA 13 223 þ 74 399 þ 67 141 þ 22** 2034 þ 801
Data are presented as mean þ S.D. n, number of animals. Student’s t-test was used for comparison with wild-type mice (*P6 0.05; **P6 0.01).
FEBS 25740 8-2-02
C.J. Miranda et al./FEBS Letters 512 (2002) 291^297294
challenge. Iron loading was obtained either by i.p. injection of
iron^dextran (85 mg/kg total), or by supplementing their diet
with carbonyl^iron (3% w/w) for a 2-month period. These two
iron loading methods a¡ect di¡erent cell types [26]. In the
liver, iron^dextran leads to iron accumulation predominantly
in Kup¡er and endothelial cells, while carbonyl^iron supple-
mentation leads to iron accumulation predominantly in hepa-
tocytes, and moderately in Kup¡er cells. Both treatments re-
sult in a statistically signi¢cant increase in iron concentration,
as determined by £ame atomic absorption spectrometry, in all
organs, with the exception of the heart in carbonyl^iron-sup-
plemented mice (Table 2). Since FRDA patients often show
¢brosis in cardiac tissue, we analyzed the hearts of
frda3=230GAA mice for ¢brosis using trichrome blue staining.
Despite the remarkably high levels of tissue iron accumulation
in the heart of iron^dextran-treated mice, collagen was practi-
cally undetectable (data not shown). Carbonyl^iron-supple-
mented diet also did not result in signi¢cant cardiac collagen
deposition (data not shown). In order to determine whether
these iron loading conditions had an e¡ect on the nervous
system and could trigger ataxia in frda3=230GAA mice, motor
coordination was assessed by rotarod. Frda3=230GAA mice per-
formed similarly to the wild-type animals (Fig. 4).
3.5. Stability of the frda230GAA allele
Large GAA repeat expansions are unstably transmitted
from parent to o¡spring, and show somatic instability in
FRDA patients [27^30]. We investigated intergenerational
GAA repeat transmission in frda3=230GAA and frda230=230GAA
mice by comparing the length of the repeat in each parent
with that observed in their progeny. No detectable change
in the GAA repeat size was found over the six studied gen-
erations (Fig. 5A). Furthermore, the GAA repeat expansion
size was the same in all analyzed tissues (Fig. 5B).
4. Discussion
The major cause of FRDA is the presence in homozygosity
of a large GAA repeat expansion in intron 1 of the frataxin
gene that decreases the level of frataxin expression. Experi-
ments using in vitro and in vivo systems revealed that the
GAA repeat interferes with transcription in an orientation-
and length-dependent manner [15,16,31]. The molecular basis
of this mechanism lead to the discovery of a novel DNA
structure that has been designated sticky DNA [32]. Large
GAA repeats lead to greater reductions in frataxin expression,
which correlate with a more severe phenotype and an earlier
age of onset. No mutations leading to a complete loss of
frataxin expression have been reported in humans, suggesting
that total frataxin de¢ciency may be incompatible with life.
This was con¢rmed by the observation that homozygous fra-
taxin knockout mice die in utero shortly after implantation
(E6.5) [22].
In order to establish an animal model for FRDA that mir-
rors the chronically reduced levels of frataxin expression
found in the human disease, we generated a knockin mouse
model that carries a (GAA)230 repeat in the frda gene. This
repeat, when in homozygosity, only leads to a decrease in
frataxin expression to 75% of wild-type levels. We further
decreased frataxin expression by generating frataxin knock-
in/knockout mice (frda3=230GAA) which show approximately
25^30% of frataxin levels compared to wild-type. This level
of frataxin is compatible with a normal embryonic develop-
ment and is associated with mild, but clinically evident FRDA
Table 2
Tissue iron concentration
Treatment n Liver Heart Pancreas Spleen
Wg Fe/g dry weight
^ 8 258 þ 69 445 þ 41 143 þ 22 1960 þ 1091
CI 6 1840 þ 1045*** 455 þ 21 175 þ 26* 6281 þ 2794**
Fe-Dex 6 22309 þ 35572 4107 þ 9812 4703 þ 19512 23407 þ 48832
CI: carbonyl^iron-enriched diet; Fe-dex: iron^dextran treatment. Data are presented as mean þ S.D. n, number of animals. Student’s t-test was
used for comparison between untreated and treated mice (*P6 0.05; **P6 0.01; ***P6 0.001; 2P6 0.0001).
Fig. 4. E¡ect of iron loading in frataxin knockout/knockin mice-rotarod analysis.
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in humans. We therefore analyzed frda3=230GAA mice for signs
of ataxia and cardiomyopathy. Rotarod analysis performed
up to the age of one year old did not reveal any motor in-
coordination in frda3=230GAA mice. The hearts of frda3=230GAA
mice were negative for iron staining. Thus, 25^30% of wild-
type frataxin levels seems to be compatible with normal neu-
rological function and iron metabolism in mice.
We studied the response of frda3=230GAA mice to challenge
with iron^dextran or carbonyl^iron and found that it did not
di¡er from the response of wild-type mice. Furthermore, iron
overload did not lead to signi¢cant cardiac ¢brosis. These
data indicate that iron per se does not trigger ataxia, nor heart
damage in mice expressing some residual frataxin. A recent
FRDA mouse model, in which frataxin is conditionally
knocked out in cardiac and skeletal muscle, develops cardio-
myopathy with intramitochondrial iron deposits speci¢cally in
cardiomyocytes. However, these deposits only appear after
other biochemical markers of mitochondrial dysfunction, par-
ticularly reduced activities of iron^sulfur enzymes, suggesting
that gross iron accumulation is a late event even in complete
frataxin de¢ciency [33].
GAA repeat instability has been reported to occur during
parent to o¡spring transmission and in somatic tissues of
FRDA patients [27^30]. We investigated intergenerational
GAA repeat transmission and the length of the repeat in
somatic tissues in frda3=230GAA and frda230=230GAA mice. We
found out that, in our mouse model, a (GAA)230 repeat is
meiotically and mitotically stable. In humans, such a repeat
is moderately unstable, so that several easily detectable
changes in size would have been identi¢ed in a similar number
of transmission events.
In summary, our study shows that: (1) low levels of fratax-
in expression close to 25^30% of wild-type levels are not as-
sociated with any obvious pathological phenotype in mice;
(2) GAA repeat lengths that are unstable in humans are
meiotically and mitotically stable in the mouse strain we in-
vestigated.
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